胰十二指肠切除术后糖尿病发展的10年前瞻性内分泌评估系列研究
该前瞻性研究纳入403例接受胰十二指肠切除术的患者,术前分类为非糖尿病和糖尿病前期,术后120个月糖尿病发生率分别为9.0%和22.0%,总体16.6%。术前糖化血红蛋白>5.4%是术后新发糖尿病的独立预测因子。
要点
- 胰十二指肠切除术后约16.6%患者新发糖尿病。
- 术前糖化血红蛋白>5.4%独立预测术后新发糖尿病。
- 术前糖尿病前期患者术后糖尿病风险是非糖尿病患者的2.471倍。
核心结论
- 胰十二指肠切除术后约16.6%患者发生糖尿病。
- 术前糖化血红蛋白>5.4%独立预测新发糖尿病。
- 术前和术后内分泌评估对患者风险分层至关重要。
研究设计与样本
- 前瞻性研究,纳入2006至2017年由资深作者连续行胰十二指肠切除术的患者。
- 排除371例糖尿病患者后,纳入403例患者,其中术前非糖尿病167例、糖尿病前期236例。
- 围术期测量空腹及餐后血浆葡萄糖、糖化血红蛋白、胰岛素和C肽,采用美国糖尿病协会定义进行血糖分类,并进行多因素风险分析。
主要发现
- 术后120个月糖尿病发生率:非糖尿病组9.0%、糖尿病前期组22.0%、总体16.6%。
- 发生糖尿病者口服葡萄糖耐量试验与空腹血糖差值(Δ)大3倍,Δ胰岛素和ΔC肽值大2倍。
- 分层多因素分析:非糖尿病组空腹血糖>95 mg/dL(RR 1.925;p=0.002)和糖尿病前期组糖化血红蛋白≥5.4%(RR 3.125;p=0.040)为糖尿病独立危险因素。
- 以任何实验室结果分类的糖尿病前期患者术后糖尿病风险是非糖尿病患者的2.471倍(p=0.001)。
- 原发病理、年龄增长或BMI与糖尿病风险增加无关联。
关键数值与推荐
- 采用美国糖尿病协会定义进行血糖分类。
- 糖化血红蛋白>5.4%的RR为2.944(p=0.047),为糖耐量受损和糖尿病的独立预测因子。
- 非糖尿病组空腹血糖>95 mg/dL的RR为1.925(p=0.002)。
- 糖尿病前期组糖化血红蛋白≥5.4%的RR为3.125(p=0.040)。
临床怎么用
- 术前应检测糖化血红蛋白和空腹血糖以进行糖尿病风险分层。
- 对糖化血红蛋白>5.4%或糖尿病前期患者加强术后血糖监测。
- 术前和术后内分泌评估应作为常规管理组成部分。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Limited literature is available on the development of impaired glucose tolerance and diabetes mellitus after pancreaticoduodenectomy. The primary aim was to define the diabetic phenotype and correlate preoperative glycemic laboratory results to new-onset diabetes after pancreaticoduodenectomy. STUDY DESIGN: In this prospective study, perioperative fasting and postprandial (oral glucose tolerance test) plasma glucose, glycated hemoglobin, insulin, and c-peptide were measured in consecutive patients undergoing pancreaticoduodenectomy by the senior author from 2006 to 2017. American Diabetes Association definitions were used for glycemic classifications. Multivariate risk factor analysis was performed. RESULTS: Of 774 identified patients, 371 diabetics were excluded and 403 patients were included: 167 and 236 were preoperatively classified as nondiabetic and prediabetic, respectively. The incidence rates of diabetes at 120 months post pancreaticoduodenectomy were 9.0% (nondiabetics), 22.0% (prediabetics), and 16.6% (overall). Patients in whom diabetes developed demonstrated a 3-fold larger difference between oral glucose tolerance test and fasting glucose (Δ), and 2-fold larger Δinsulin and Δc-peptide values. Tiered multivariate analysis identified glycated hemoglobin >5.4% with a relative risk (RR) of 2.944 (p = 0.047) as an independent predictor of impaired glucose tolerance and diabetes mellitus. Analysis of patients stratified by preoperative classification identified fasting glucose >95 mg/dL (nondiabetics, RR 1.925; p = 0.002), and glycated hemoglobin ≥5.4% (prediabetics, RR 3.125; p = 0.040) as independent risk factors for diabetes. Compared with nondiabetics, prediabetics classified by any laboratory results demonstrated an RR of 2.471 (p = 0.001) for diabetes developing postoperatively. There was no association between primary pathology, advancing age, or BMI and increased risk of diabetes development. CONCLUSIONS: Diabetes will develop after pancreaticoduodenectomy in approximately 16.6% of patients. A preoperative glycated hemoglobin >5.4% independently predicts new-onset diabetes. Pre- and postoperative endocrine analysis remains paramount for proper patient risk stratification.
引用
- Maxwell DW, Jajja MR, Tariq M, et al. Development of Diabetes after Pancreaticoduodenectomy: Results of a 10-Year Series Using Prospective Endocrine Evaluation. J Am Coll Surg. 2019. PMID: 30690075. doi:10.1016/j.jamcollsurg.2018.12.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。